349 related articles for article (PubMed ID: 20594138)
21. Combination immunomodulator and antibiotic treatment in patients with inflammatory bowel disease and clostridium difficile infection.
Ben-Horin S; Margalit M; Bossuyt P; Maul J; Shapira Y; Bojic D; Chermesh I; Al-Rifai A; Schoepfer A; Bosani M; Allez M; Lakatos PL; Bossa F; Eser A; Stefanelli T; Carbonnel F; Katsanos K; Checchin D; Miera IS; Chowers Y; Moran GW;
Clin Gastroenterol Hepatol; 2009 Sep; 7(9):981-7. PubMed ID: 19523534
[TBL] [Abstract][Full Text] [Related]
22. Effectiveness of infliximab in Brazilian children and adolescents with Crohn disease and ulcerative colitis according to clinical manifestations, activity indices of inflammatory bowel disease, and corticosteroid use.
Tiemi J; Komati S; Sdepanian VL
J Pediatr Gastroenterol Nutr; 2010 Jun; 50(6):628-33. PubMed ID: 20386321
[TBL] [Abstract][Full Text] [Related]
23. New patients: should children be treated differently?
Dubinsky MC
Colorectal Dis; 2006 May; 8 Suppl 1():15-9. PubMed ID: 16594959
[TBL] [Abstract][Full Text] [Related]
24. Recent advances using immunomodulators for inflammatory bowel disease.
Nielsen OH; Bjerrum JT; Herfarth H; Rogler G
J Clin Pharmacol; 2013 Jun; 53(6):575-88. PubMed ID: 23408468
[TBL] [Abstract][Full Text] [Related]
25. Treatment with biologic therapies and the risk of cancer in patients with IBD.
Biancone L; Calabrese E; Petruzziello C; Pallone F
Nat Clin Pract Gastroenterol Hepatol; 2007 Feb; 4(2):78-91. PubMed ID: 17268543
[TBL] [Abstract][Full Text] [Related]
26. Infliximab-induced psoriasis in children with inflammatory bowel disease.
Hiremath G; Duffy L; Leibowitz I
J Pediatr Gastroenterol Nutr; 2011 Feb; 52(2):230-2. PubMed ID: 21240020
[TBL] [Abstract][Full Text] [Related]
27. [Azathioprine, 6-mercaptopurine, and inflammatory diseases of the intestine].
Beaugerie L; Gendre JP
Gastroenterol Clin Biol; 1990; 14(3):230-40. PubMed ID: 2188863
[No Abstract] [Full Text] [Related]
28. [Current medical treatment of inflammatory bowel disease].
Bosques-Padilla F
Rev Gastroenterol Mex; 2007 Nov; 72 Suppl 2():92-101. PubMed ID: 18277494
[No Abstract] [Full Text] [Related]
29. What's new: innovative concepts in inflammatory bowel disease.
Sandborn WJ
Colorectal Dis; 2006 May; 8 Suppl 1():3-9. PubMed ID: 16594957
[TBL] [Abstract][Full Text] [Related]
30. [Biological treatment of inflammatory bowel diseases in children in the years 2004-2013 in Poland].
Iwańczak B; Ryzko J; Kierkuś J; Jankowski P; Sładek M; Wasilewska A; Landowski P; Szczepanik M; Krzesiek E; Sienkiewicz E; Szaflarska-Popławska A; Wiecek S; Kwiecien J; Kacperska M; Korczowski B; Maślana J
Pol Merkur Lekarski; 2014 May; 36(215):311-5. PubMed ID: 24964507
[TBL] [Abstract][Full Text] [Related]
31. Immunosuppression in inflammatory bowel disease: traditional, biological or both?
Van Assche G; Vermeire S; Rutgeerts P
Curr Opin Gastroenterol; 2009 Jul; 25(4):323-8. PubMed ID: 19417645
[TBL] [Abstract][Full Text] [Related]
32. Use of corticosteroids, immunomodulators, and infliximab at a third-level Day-Hospital Service of Gastro-Hepatology.
Actis GC; Pellicano R; Bugianesi E; Lagget M; Rizzetto M
Minerva Gastroenterol Dietol; 2008 Sep; 54(3):239-42. PubMed ID: 18614972
[TBL] [Abstract][Full Text] [Related]
33. Mechanisms and efficacy of immunobiologic therapies for inflammatory bowel diseases.
Ghosh N; Chaki R; Mandal V; Lin GD; Mandal SC
Int Rev Immunol; 2010; 29(1):4-37. PubMed ID: 20100080
[TBL] [Abstract][Full Text] [Related]
34. [Inflammatory diseases of the intestines].
Felley C; Guyot J; Hess J; Mottet C; Delarive J; Michetti P
Rev Med Suisse; 2006 Jan; 2(49):191-4, 196-8, 201-3. PubMed ID: 16493962
[TBL] [Abstract][Full Text] [Related]
35. Current status of drug therapy for inflammatory bowel disease.
Peppercorn MA
Compr Ther; 1985 Dec; 11(12):14-9. PubMed ID: 2866866
[TBL] [Abstract][Full Text] [Related]
36. How to improve the safety of biologic therapy in Crohn's disease.
Ferkolj I
J Physiol Pharmacol; 2009 Dec; 60 Suppl 7():67-70. PubMed ID: 20388947
[TBL] [Abstract][Full Text] [Related]
37. American Gastroenterological Association Institute technical review on the use of thiopurines, methotrexate, and anti-TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease.
Dassopoulos T; Sultan S; Falck-Ytter YT; Inadomi JM; Hanauer SB
Gastroenterology; 2013 Dec; 145(6):1464-78.e1-5. PubMed ID: 24267475
[No Abstract] [Full Text] [Related]
38. [Anti-TNF biologics in the treatment of chronic inflammatory bowel disease].
Nikolaus S; Schreiber S
Internist (Berl); 2008 Aug; 49(8):947-8, 950-3. PubMed ID: 18584139
[TBL] [Abstract][Full Text] [Related]
39. Insights in immunomodulatory therapies for ulcerative colitis and Crohn's disease.
Nguyen GC; Harris ML; Dassopoulos T
Curr Gastroenterol Rep; 2006 Dec; 8(6):499-505. PubMed ID: 17105689
[TBL] [Abstract][Full Text] [Related]
40. Positioning biologic therapy for Crohn's disease and ulcerative colitis.
Velayos FS; Sandborn WJ
Curr Gastroenterol Rep; 2007 Dec; 9(6):521-7. PubMed ID: 18377806
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
